Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs

Neurochemistry International

Volumn 55, Issue 1-3, 2009, Pages 85-97

  Wierońska, Joanna M ^a   Pilc, Andrzej ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anxiety; Astrocyte; Depression; Metabotropic glutamate receptors; Schizophrenia; Tripartite synapse

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMN 082; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOZAPINE; DIAZEPAM; EGLUMETAD; FENOBAM; HALOPERIDOL; LY 3544740; LY 487379; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; TALAGLUMETAD; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; AMNESIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG BINDING; HUMAN; MOOD DISORDER; MUSCLE RELAXATION; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANQUILIZING ACTIVITY; WEIGHT CHANGE; WEIGHT GAIN;

ANIMALS; ANXIETY; DEPRESSIVE DISORDER; GLUTAMIC ACID; HUMANS; MENTAL DISORDERS; NEUROGLIA; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SYNAPSES;

ANIMALIA;

EID: 64949091023     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.02.019     Document Type: Article

References (191)

1. Alfonso J., Frick L.R., Silberman D.M., Palumbo M.L., Genaro A.M., and Frasch A.C. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biol. Psychiatry 59 (2006) 244-251
2. Alfonso J., Pollevick G.D., Van Der Hart M.G., Flugge G., Fuchs E., and Frasch A.C. Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur. J. Neurosci. 19 (2004) 659-666
3. Allen N.J., and Barres B.A. Signaling between glia and neurons: focus on synaptic plasticity. Curr. Opin. Neurobiol. 15 (2005) 542-548
4. Amminger G.P., Leicester S., Yung A.R., Phillips L.J., Berger G.E., Francey S.M., Yuen H.P., and McGorry P.D. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr. Res. 84 (2006) 67-76
5. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., Tehrani L., Bradbury M.J., Cosford N.D., and Varney M.A. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1044-1051
6. Andlin-Sobocki P., Jonsson B., Wittchen H.U., and Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 12 Suppl. 1 (2005) 1-27
7. Angelucci F., Mathe A.A., and Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog. Brain Res. 146 (2004) 151-165
8. Aparicio-Legarza M.I., Davis B., Hutson P.H., and Reynolds G.P. Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients. Neurosci. Lett. 241 (1998) 143-146
9. Araque A., Parpura V., Sanzgiri R.P., and Haydon P.G. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22 (1999) 208-215
10. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., and Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry (2008)
11. Banasr M., and Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol. Psychiatry 64 (2008) 863-870
12. Barres B.A. Five electrophysiological properties of glial cells. Ann. N. Y. Acad. Sci. 633 (1991) 248-254
13. Barres B.A. Glial ion channels. Curr. Opin. Neurobiol. 1 (1991) 354-359
14. Barres B.A. New roles for glia. J. Neurosci. 11 (1991) 3685-3694
15. Belozertseva I.V., Kos T., Popik P., Danysz W., and Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 17 (2007) 172-179
16. Bergink V., and Westenberg H.G. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int. Clin. Psychopharmacol. 20 (2005) 291-293
17. Bergles D.E., and Jahr C.E. Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron 19 (1997) 1297-1308
18. Besong G., Battaglia G., D'Onofrio M., Di Marco R., Ngomba R.T., Storto M., Castiglione M., Mangano K., Busceti C.L., Nicoletti F.R., Bacon K., Tusche M., Valenti O., Conn P.J., Bruno V., and Nicoletti F. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J. Neurosci. 22 (2002) 5403-5411
19. Bespalov A.Y., van Gaalen M.M., Sukhotina I.A., Wicke K., Mezler M., Schoemaker H., and Gross G. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur. J. Pharmacol. 592 (2008) 96-102
20. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., and Volterra A. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391 (1998) 281-285
21. Bockaert J., and Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18 (1999) 1723-1729
22. Bockaert J., Roussignol G., Becamel C., Gavarini S., Joubert L., Dumuis A., Fagni L., and Marin P. GPCR-interacting proteins (GIPs): nature and functions. Biochem. Soc. Trans. 32 (2004) 851-855
23. Bowley M.P., Drevets W.C., Ongur D., and Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biol. Psychiatry 52 (2002) 404-412
24. Bridges T.M., and Lindsley C.W. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem. Biol. 3 (2008) 530-541
25. Brown S., Inskip H., and Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 177 (2000) 212-217
26. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., and Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 18 (1998) 9594-9600
27. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., and Cosford N.D. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29 (2004) 1971-1979
28. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh) 20 (1963) 140-144
29. Cassano P., and Fava M. Depression and public health: an overview. J. Psychosom. Res. 53 (2002) 849-857
30. Chaki, S., Okubo, T., Sekiguchi, Y., 2006. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Patents. CNS. Drug Discov. 1, 1-27.
31. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney Jr. W.E., Akil H., Watson S.J., and Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 15653-15658
32. Ciccarelli R., Di Iorio P., Bruno V., Battaglia G., D'Alimonte I., D'Onofrio M., Nicoletti F., and Caciagli F. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27 (1999) 275-281
33. Coco S., Calegari F., and Pravettoni E. Storage and release of ATP from astrocytes in cultures. J. Biol. Chem. 278 2 (2003) 1354-1362
34. Cormier R.J., Mennerick S., Melbostad H., and Zorumski C.F. Basal levels of adenosine modulate mGluR5 on rat hippocampal astrocytes. Glia 33 (2001) 24-35
35. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46 (2003) 204-206
36. Coyle J.T., Tsai G., and Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets. CNS Neurol. Disord. 1 (2002) 183-189
37. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., and van der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 17 (2003) 2409-2417
38. D'Antoni S., Berretta A., Bonaccorso C.M., Bruno V., Aronica E., Nicoletti F., and Catania M.V. Metabotropic glutamate receptors in glial cells. Neurochem. Res. 33 (2008) 2436-2443
39. De Keyser J., Mostert J.P., and Koch M.W. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 267 (2008) 3-16
40. Duman R.S., and Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59 (2006) 1116-1127
41. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., and Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33 (2008) 1603-1610
42. Dunn R.W., Corbett R., and Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur. J. Pharmacol. 169 (1989) 1-10
43. Fatemi S.H., Laurence J.A., Araghi-Niknam M., Stary J.M., Schulz S.C., Lee S., and Gottesman I.I. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr. Res. 69 (2004) 317-323
44. Fellin T., D'Ascenzo M., and Haydon P.G. Astrocytes control neuronal excitability in the nucleus accumbens. Sci. World J. 7 (2007) 89-97
45. Feyissa A.M., Chandran A., Stockmeier C.A., and Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2008)
46. Galici R., Echemendia N.G., Rodriguez A.L., and Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315 (2005) 1181-1187
47. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., and Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 318 (2006) 173-185
48. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G.R., Gavioli E.C., Kapczinski F., and Quevedo J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 140-144
49. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
50. Gegelashvili G., Dehnes Y., and Danbolt N.C. The high-affinity glutamate transporters GLT1, GLAST and EAAT4 are regulated via different signalling mechanisms. Neurochem. Int. 37 (2000) 163-170
51. Geurts J.J., Wolswijk G., Bo L., van D.V., Polman C.H., Troost D., and Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126 (2003) 1755-1766
52. Goldner E.M., Hsu L., Waraich P., and Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry 47 (2002) 833-843
53. Grillon C., Cordova J., Levine L.R., and Morgan III C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl.) 168 (2003) 446-454
54. Grosche J., Matyash V., Moller T., Verkhratsky A., Reichenbach A., and Kettenmann H. Microdomains for neuron-glia interaction: parallel fiber signaling to Bergmann glial cells. Nat. Neurosci. 2 (1999) 139-143
55. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., and McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 30 (2007) 47-57
56. Halassa M.M., Fellin T., Takano H., Dong J.H., and Haydon P.G. Synaptic islands defined by the territory of a single astrocyte. J. Neurosci. 27 (2007) 6473-6477
57. Hansson E., Blomstrand F., Khatibi S., Olsson T., and Ronnback L. Glutamate induced astroglial swelling-methods and mechanisms. Acta Neurochir. Suppl. 70 (1997) 148-151
58. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
59. Hashimoto K., Sawa A., and Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62 (2007) 1310-1316
60. Haydon P.G. GLIA: listening and talking to the synapse. Nat. Rev. Neurosci. 2 (2001) 185-193
61. Haydon P.G., and Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 86 (2006) 1009-1031
62. Heidbreder C.A., Bianchi M., Lacroix L.P., Faedo S., Perdona E., Remelli R., Cavanni P., and Crespi F. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50 (2003) 269-276
63. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., and Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284 (1998) 651-660
64. Heresco-Levy U. N-methyl-d-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int. J. Neuropsychopharmacol. 3 (2000) 243-258
65. Hertz L., and Zielke H.R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 27 (2004) 735-743
66. Janssens N., and Lesage A.S. Glutamate receptor subunit expression in primary neuronal and secondary glial cultures. J. Neurochem. 77 (2001) 1457-1474
67. Jarosik J., Legutko B., Unsicker K., and Bohlen und H.O. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp. Neurol. 204 (2007) 20-28
68. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9 (1987) 12-35
69. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizzano J.P., and Schoepp D.D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl.) 179 (2005) 271-283
70. Jourdain P., Bergersen L.H., Bhaukaurally K., Bezzi P., Santello M., Domercq M., Matute C., Tonello F., Gundersen V., and Volterra A. Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci. 10 (2007) 331-339
71. Kammermeier P.J. Endogenous homer proteins regulate metabotropic glutamate receptor signaling in neurons. J. Neurosci. 28 (2008) 8560-8567
72. Kammermeier P.J., and Worley P.F. Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 6055-6060
73. Kammermeier P.J., and Yun J. Activation of metabotropic glutamate receptor 1 dimers requires glutamate binding in both subunits. J. Pharmacol. Exp. Ther. 312 (2005) 502-508
74. Kellner M., Muhtz C., Stark K., Yassouridis A., Arlt J., and Wiedemann K. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl.) 179 (2005) 310-315
75. Kew J.N., and Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 179 (2005) 4-29
76. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Chen T.B., Wisnoski D.D., Lindsley C.W., Tiller P.R., Smith S., Jacobson M.A., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., and Williams Jr. D.L. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313 (2005) 199-206
77. Kirsch I. Antidepressant drugs 'work', but they are not clinically effective. Br. J. Hosp. Med. (Lond.) 69 (2008) 359
78. Klak K., Palucha A., Branski P., Sowa M., and Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids (2006)
79. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., Nowak G., Cosford N.D., and Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47 (2004) 342-350
80. Klodzinska A., Tatarczynska E., Chojnacka-Wojcik E., and Pilc A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. Pol. J. Pharmacol. 52 (2000) 463-466
81. Klodzinska A., Tatarczynska E., Stachowicz K., and Chojnacka-Wojcik E. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J. Physiol. Pharmacol. 55 (2004) 113-126
82. Kniazeff J., Bessis A.S., Maurel D., Ansanay H., Prezeau L., and Pin J.P. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat. Struct. Mol. Biol. 11 (2004) 706-713
83. Knoflach F., Mutel V., Jolidon S., Kew J.N., Malherbe P., Vieira E., Wichmann J., and Kemp J.A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13402-13407
84. Kollmar R., Markovic K., Thurauf N., Schmitt H., and Kornhuber J. Ketamine followed by memantine for the treatment of major depression. Aust. N. Z. J. Psychiatry 42 (2008) 170
85. Kondziella D., Brenner E., Eyjolfsson E.M., Markinhuhta K.R., Carlsson M.L., and Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 31 (2006) 1880-1887
86. Kondziella D., Brenner E., Eyjolfsson E.M., and Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem. Int. 50 (2007) 291-301
87. Largo C., Cuevas P., Somjen G.G., Martin D.R., and Herreras O. The effect of depressing glial function in rat brain in situ on ion homeostasis, synaptic transmission, and neuron survival. J. Neurosci. 16 (1996) 1219-1229
88. Lavreysen H., and Dautzenberg F.M. Therapeutic potential of group III metabotropic glutamate receptors. Curr. Med. Chem. 15 (2008) 671-684
89. Layer R.T., Popik P., Olds T., and Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52 (1995) 621-627
90. Lee K.M., and Kim Y.K. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 6 (2006) 1298-1304
91. Leonard B.E., and Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int. Rev. Neurobiol. 22 (1981) 251-286
92. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
93. Li X., Need A.B., Baez M., and Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. 319 (2006) 254-259
94. Li Y.F., Jackson K.L., Stern J.E., Rabeler B., and Patel K.P. Interaction between glutamate and GABA systems in the integration of sympathetic outflow by the paraventricular nucleus of the hypothalamus. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H2847-H2856
95. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
96. Lydiard R.B. The role of GABA in anxiety disorders. J. Clin. Psychiatry 64 Suppl. 3 (2003) 21-27
97. Margis R., Zanatto V.C., Tramontina F., Vinade E., Lhullier F., Portela L.V., Souza D.O., Dalmaz C., Kapczinski F., and Goncalves C.A. Changes in S100B cerebrospinal fluid levels of rats subjected to predator stress. Brain Res. 1028 (2004) 213-218
98. Mathiesen J.M., Svendsen N., Brauner-Osborne H., Thomsen C., and Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br. J. Pharmacol. 138 (2003) 1026-1030
99. Matute C., Melone M., Vallejo-Illarramendi A., and Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49 (2005) 451-455
100. May L.T., Leach K., Sexton P.M., and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
101. Melone M., Bellesi M., and Conti F. Synaptic localization of GLT-1a in the rat somatic sensory cortex. Glia 57 (2009) 108-117
102. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., Pellegrini-Giampietro D.E., Rothstein J.D., and Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol. Psychiatry 6 (2001) 380-386
103. Melzer D., Fryers T., Jenkins R., Brugha T., and McWilliams B. Social position and the common mental disorders with disability: estimates from the National Psychiatric Survey of Great Britain. Soc. Psychiatry Psychiatr. Epidemiol. 38 (2003) 238-243
104. Mennerick S., and Zorumski C.F. Glial contributions to excitatory neurotransmission in cultured hippocampal cells. Nature 368 (1994) 59-62
105. Miguel-Hidalgo J.J., and Rajkowska G. Comparison of prefrontal cell pathology between depression and alcohol dependence. J. Psychiatr. Res. 37 (2003) 411-420
106. Mineff E., and Valtschanoff J. Metabotropic glutamate receptors 2 and 3 expressed by astrocytes in rat ventrobasal thalamus. Neurosci. Lett. 270 (1999) 95-98
107. Mitsukawa K., Mombereau C., Lotscher E., Uzunov D.P., van der Putten .H., Flor P.J., and Cryan J.F. Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 31 (2006) 1112-1122
108. Mitterauer B. Imbalance of glial-neuronal interaction in synapses: a possible mechanism of the pathophysiology of bipolar disorder. Neuroscientist 10 (2004) 199-206
109. Mitterauer B. Nonfunctional glial proteins in tripartite synapses: a pathophysiological model of schizophrenia. Neuroscientist 11 (2005) 192-198
110. Mitterauer B.J. Where and how could intentional programs be generated in the brain? A hypothetical model based on glial-neuronal interactions. Biosystems 88 (2007) 101-112
111. Moghaddam B., Bolinao M.L., Stein-Behrens B., and Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res. 655 (1994) 251-254
112. Moldrich R.X., and Beart P.M. Emerging signalling and protein interactions mediated via metabotropic glutamate receptors. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 109-122
113. Molina-Hernandez M., Tellez-Alcantara N.P., Perez-Garcia J., Olivera-Lopez J.I., and Jaramillo M.T. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1129-1135
114. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., and Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40 (1997) 528-537
115. Mothet J.P., Pollegioni L., Ouanounou G., Martineau M., Fossier P., and Baux G. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter d-serine. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 5606-5611
116. Narita M., Kuzumaki N., Narita M., Kaneko C., Tamai E., Khotib J., Miyatake M., Shindo K., Nagumo Y., Tanaka S., and Suzuki T. Age-related emotionality is associated with cortical delta-opioid receptor dysfunction-dependent astrogliosis. Neuroscience 137 (2006) 1359-1367
117. Nedergaard M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science 263 (1994) 1768-1771
118. Nemeroff C.B. Anxiolytics: past, present, and future agents. J. Clin. Psychiatry 64 Suppl. 3 (2003) 3-6
119. Nemeroff C.B. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. 37 (2003) 133-146
120. Nilsson M., Carlsson A., and Carlsson M.L. Glycine and d-serine decrease MK-801-induced hyperactivity in mice. J. Neural Transm. 104 (1997) 1195-1205
121. Nudmamud S., and Reynolds G.P. Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci. Lett. 304 (2001) 9-12
122. O'Leary D.M., Movsesyan V., Vicini S., and Faden A.I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131 (2000) 1429-1437
123. Palucha A., Branski P., Szewczyk B., Wieronska J.M., Klak K., and Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav. 81 (2005) 901-906
124. Palucha A., Klak K., Branski P., van der Putten H., Flor P.J., and Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl.) (2007)
125. Palucha A., and Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther. 115 (2007) 116-147
126. Palucha A., Tatarczynska E., Branski P., Szewczyk B., Wieronska J.M., Klak K., Chojnacka-Wojcik E., Nowak G., and Pilc A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 46 (2004) 151-159
127. Palucha-Poniewiera A., Klodzinska A., Stachowicz K., Tokarski K., Hess G., Schann S., Frauli M., Neuville P., and Pilc A. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55 (2008) 517-524
128. Panatier A., Theodosis D.T., Mothet J.P., Touquet B., Pollegioni L., Poulain D.A., and Oliet S.H. Glia-derived d-serine controls NMDA receptor activity and synaptic memory. Cell 125 (2006) 775-784
129. Papp M., and Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol. J. Pharmacol. 45 (1993) 549-553
130. Papp M., and Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263 (1994) 1-7
131. Pecknold J.C., McClure D.J., Appeltauer L., Wrzesinski L., and Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2 (1982) 129-133
132. Perea G., and Araque A. Communication between astrocytes and neurons: a complex language. J. Physiol. Paris 96 (2002) 199-207
133. Phillips T., Makoff A., Murrison E., Mimmack M., Waldvogel H., Faull R., Rees S., and Emson P. Immunohistochemical localisation of mGluR7 protein in the rodent and human cerebellar cortex using subtype specific antibodies. Brain Res. Mol. Brain Res. 57 (1998) 132-141
134. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
135. Pilc A., Klodzinska A., Branski P., Nowak G., Palucha A., Szewczyk B., Tatarczynska E., Chojnacka-Wojcik E., and Wieronska J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43 (2002) 181-187
136. Pin J.P., and Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 (1995) 1-26
137. Poleszak E., Wlaz P., Wrobel A., Dybala M., Sowa M., Fidecka S., Pilc A., and Nowak G. Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol. Rep. 59 (2007) 595-600
138. Porsolt R.D., Joyce D., and Summerfield A. Amphetamine-barbiturate mixtures: learning and retention in rats. Act. Nerv. Super. (Praha) 13 (1971) 75-77
139. Porter R.H., Jaeschke G., Spooren W., Ballard T.M., Buttelmann B., Kolczewski S., Peters J.U., Prinssen E., Wichmann J., Vieira E., Muhlemann A., Gatti S., Mutel V., and Malherbe P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315 (2005) 711-721
140. Przegalinski E., Tatarczynska E., and Chojnacka-Wojcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39 (2000) 1858-1864
141. Przegalinski E., Tatarczynska E., Deren-Wesolek A., and Chojnacka-Wojcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 54 (1996) 73-77
142. Redmond A.M., Kelly J.P., and Leonard B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol. Biochem. Behav. 58 (1997) 355-359
143. Rogoz Z., and Legutko B. Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol. Rep. 57 (2005) 840-844
144. Rogoz Z., Skuza G., and Legutko B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J. Physiol. Pharmacol. 56 (2005) 661-671
145. Rorick-Kehn L.M., Perkins E.J., Knitowski K.M., Hart J.C., Johnson B.G., Schoepp D.D., and McKinzie D.L. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J. Pharmacol. Exp. Ther. 316 (2006) 905-913
146. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., Suslow T., Peters M., Kaestner F., Heindel W., Arolt V., and Pfleiderer B. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 361-364
147. Scaccianoce S., Del Bianco P., Pannitteri G., and Passarelli F. Relationship between stress and circulating levels of S100B protein. Brain Res. 1004 (2004) 208-211
148. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299 (2001) 12-20
149. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., and Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6 (2003) 189-197
150. Schousboe A. Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem. Res. 28 (2003) 347-352
151. Silva G.A., Theriault E., Mills L.R., Pennefather P.S., and Feeney C.J. Group I and II metabotropic glutamate receptor expression in cultured rat spinal cord astrocytes. Neurosci. Lett. 263 (1999) 117-120
152. Smit A.B., Syed N.I., Schaap D., van Minnen J., Klumperman J., Kits K.S., Lodder H., van der Schors R.C., van Elk R., Sorgedrager B., Brejc K., Sixma T.K., and Geraerts W.P. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 411 (2001) 261-268
153. Sontheimer H. Voltage-dependent ion channels in glial cells. Glia 11 (1994) 156-172
154. Spooren W.P., Schoeffter P., Gasparini F., Kuhn R., and Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 435 (2002) 161-170
155. Stachowicz K., Branski P., Klak K., van der Putten H., Cryan J.F., Flor P.J., and Andrzej P. Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behav. Pharmacol. 19 (2008) 597-603
156. Stachowicz K., Chojnacka-Wojcik E., Klak K., and Pilc A. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology 52 (2007) 306-312
157. Stachowicz K., Klak K., Klodzinska A., Chojnacka-Wojcik E., and Pilc A. Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur. J. Pharmacol. 498 (2004) 153-156
158. Steckler T., Lavreysen H., Oliveira A.M., Aerts N., Van Craenendonck H., Prickaerts J., Megens A., and Lesage A.S. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl.) 179 (2005) 198-206
159. Steindler D.A. Glial boundaries in the developing nervous system. Annu. Rev. Neurosci. 16 (1993) 445-470
160. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., Brisch R., Gos T., Mawrin C., Myint A.M., and Bogerts B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J. Psychiatr. Res. 42 (2008) 868-876
161. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.) 85 (1985) 367-370
162. Sutcigil L., Oktenli C., Musabak U., Bozkurt A., Cansever A., Uzun O., Sanisoglu S.Y., Yesilova Z., Ozmenler N., Ozsahin A., and Sengul A. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol. 2007 (2007) 76396
163. Tamaru Y., Nomura S., Mizuno N., and Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106 (2001) 481-503
164. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
165. Tatarczynska E., Klodzinska A., Kroczka B., Chojnacka-Wojcik E., and Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl.) 158 (2001) 94-99
166. Tatarczynska E., Palucha A., Szewczyk B., Chojnacka-Wojcik E., Wieronska J., and Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol. J. Pharmacol. 54 (2002) 707-710
167. Taylor D.L., Diemel L.T., Cuzner M.L., and Pocock J.M. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J. Neurochem. 82 (2002) 1179-1191
168. Teichberg V.I. Glial glutamate receptors: likely actors in brain signaling. FASEB J. 5 (1991) 3086-3091
169. Tokarski K., Bobula B., Wabno J., and Hess G. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 153 (2008) 789-795
170. Trullas R., Folio T., Young A., Miller R., Boje K., and Skolnick P. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203 (1991) 379-385
171. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44 (1998) 1081-1089
172. Turrigiano G.G., and Nelson S.B. Homeostatic plasticity in the developing nervous system. Nat. Rev. Neurosci. 5 (2004) 97-107
173. Vallejo-Illarramendi A., Torres-Ramos M., Melone M., Conti F., and Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50 (2005) 276-279
174. Varon S.S., and Somjen G.G. Neuron-glia interactions. Neurosci. Res. Program. Bull. 17 (1979) 1-239
175. Varty G.B., Grilli M., Forlani A., Fredduzzi S., Grzelak M.E., Guthrie D.H., Hodgson R.A., Lu S.X., Nicolussi E., Pond A.J., Parker E.M., Hunter J.C., Higgins G.A., Reggiani A., and Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl.) 179 (2005) 207-217
176. Vemeiren C., Najimi M., and Vanhoutte N. Acute up-regulation of glutamate uptake mediated by mGluR5a in reactive astrocytes. J. Nurochemistry. 4 (2005) 405-416
177. Venero J.L., Santiago M., Tomas-Camardiel M., Matarredona E.R., Cano J., and Machado A. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neuroscience 113 (2002) 857-869
178. Volterra A., and Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat. Rev. Neurosci. 6 (2005) 626-640
179. Volterra A., and Steinhauser C. Glial modulation of synaptic transmission in the hippocampus. Glia 47 (2004) 249-257
180. Wieronska J.M., Papp M., and Pilc A. Effects of anxiolytic drugs on some behavioral consequences in olfactory bulbectomized rats. Pol. J. Pharmacol. 53 (2001) 517-525
181. Wieronska J.M., Szewczyk B., Branski P., Palucha A., and Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23 (2002) 213-216
182. Wieronska J.M., Szewczyk B., Palucha A., Branski P., Zieba B., and Smialowska M. Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacol. Rep. 57 (2005) 734-743
183. Willetts J., Balster R.L., and Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11 (1990) 423-428
184. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16 (1992) 525-534
185. Wroblewska B., Wegorzewska I.N., Bzdega T., Olszewski R.T., and Neale J.H. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J. Neurochem. 96 (2006) 1071-1077
186. Yao H., Ding J.H., Zhou F., and Wang F. Enhancement of glutamate uptake mediates the neuroprotection exerted by activation group II or III metabotropic glutamate receptors on astrocytes. J. Neurochem. 92 (2005) 9948-9961
187. Yasuhara A., Nakamura M., Sakagami K., Shimazaki T., Yoshikawa R., Chaki S., Ohta H., and Nakazato A. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarbo xylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg. Med. Chem. 14 (2006) 4193-4207
188. Ye Z.C., and Sontheimer H. Metabotropic glutamate receptor agonists reduce glutamate release from cultured astrocytes. Glia 25 (1999) 270-281
189. Yuan F., and Wang T. Glutamate-induced swelling of cultured astrocytes is mediated by metabotropic glutamate receptor. Sci. China C Life Sci. 39 (1996) 517-522
190. Zarate Jr. C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., and Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63 (2006) 856-864
191. Zhang J.M., Wang H.K., Ye C.Q., Ge W., Chen Y., Jiang Z.L., Wu C.P., Poo M.M., and Duan S. ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. Neuron 40 (2003) 971-982